Assessing efficacy of indacaterol in moderate and severe COPD patients: A 12-week study in an Asian population

Respiratory Medicine

Volumn 106, Issue 12, 2012, Pages 1715-1721

  To, Yasuo ^a   Kinoshita, Masaharu ^b   Lee, Sang Haak ^c   Hang, Liang Wen ^d   Ichinose, Masakazu ^e   Fukuchi, Yoshinosuke ^f   Kitawaki, Tetsuji ^g   Okino, Naoko ^g   Prasad, Niyati ^h   Lawrence, David ^h   Kramer, Benjamin ⁱ  

^a Fraternity Memorial Hospital Tokyo   (Japan)

^b Nagata Hospital   (Japan)

^c The Catholic University of Korea   (South Korea)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TOHOKU UNIVERSITY   (Japan)

^f JUNTENDO UNIVERSITY   (Japan)

^g Novartis   (Japan)

^h Novartis Pharmaceuticals UK Limited   (United Kingdom)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Asian population; Bronchodilator; COPD; Efficacy; Indacaterol; Safety

Indexed keywords

CORTICOSTEROID; INDACATEROL; PLACEBO;

ADULT; ARTICLE; ASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HONG KONG; HUMAN; INDIA; JAPAN; KOREA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGAPORE; ST GEORGE RESPIRATORY QUESTIONNAIRE; TAIWAN; TRANSITION DSYPNEA INDEX; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ASIA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SLEEP DISORDERS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84867742133     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.09.002     Document Type: Article

References (23)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2011. At: www.goldcopd.org [accessed 28.01.12].
2. S. Appleton, P. Poole, B. Smith, T.J. Lasserson, M.M.K. Chan, and C.J. Cates Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease Cochrane Database Syst Rev 3 2006 CD001104
3. P.J. Barnes, J.M. Drazen, S.I. Rennard, and N.C. Thomson Asthma and COPD: basic mechanisms and clinical management 2nd ed. 2008 Academic Press p. 624
4. 2-agonists in development for asthma and chronic obstructive pulmonary disease Expert Opin Investig Drugs 14 2005 775 783
5. 2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
6. J.F. Donohue, C. Fogarty, J. Lötvall, D.A. Mahler, H. Worth, A. Yorgancioglu for the INHANCE study investigators Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 2010 155 162
7. G. Feldman, T. Siler, N. Prasad, D. Jack, S. Piggott, and R. Owen Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study BMC Pulm Med 10 2010 1 9
8. O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, and C. Lassen Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 2011 273 279
9. M. Hosoe, R. Woessner, S. Matsushima, D. Lawrence, and B. Kramer Efficacy and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of two randomized placebo-controlled studies Clin Drug Invest 31 2011 247 255
10. M. Kato, H. Makita, K. Uemura, Y. Fukuchi, M. Hosoe, and C. Emery Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: a randomized, double-blind, placebo-controlled trial Allergol Int 59 2010 285 293
11. M. Kinoshita, S.-H. Lee, L.-W. Hang, M. Ichinose, M. Hosoe, N. Okino for the Indacaterol Asian COPD study investigators Efficacy and safety of indacaterol 150 and 300μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo controlled study Respirology 17 2012 379 389
12. European Medicines Agency (EMA). Onbrez breezhaler (indacaterol) at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 001114/human-med-001219.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d124&jsenabled=true (accessed 28.02.12).
13. 2-agonist, in subjects with COPD: a randomized, placebo-controlled study Chest 140 2011 69 75
14. S.I. Rennard, and J. Vestbo The many "small COPDs": COPD should be an orphan disease Chest 134 2008 623 627
15. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the Diagnosis, management, and prevention of chronic obstructive pulmonary disease www.goldcopd.org 2005
16. D.A. Mahler, and T.J. Witek Jr. The MCID of the transition dyspnoea index is a total score of one unit COPD 2 2005 99 103
17. P.W. Jones St. George's Respiratory Questionnaire: MCID COPD 2 2005 75 79
18. K.F. Rabe Improving dyspnea in chronic obstructive pulmonary disease Proc Am Thorac Soc 3 2006 270 275
19. Korn S, Kornmann O, Dunn L, Lassen C, Lawrence D, Kramer B. Efficacy of indacaterol is maintained in patients with moderate or less and severe or worse COPD. In: Presented at European Respiratory Society; 2011. p. 860.
20. E. Stahl, S.-E. Jansson, A.-C. Jonsson, K. Svensson, B. Lundback, and F. Andersson Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD Health Qual Outcome 1 2003 18
21. N. Gooneratne Cardiopulmonary disorders affecting sleep in the elderly N. Butkov, T. Lee-Chiong, Fundamentals of sleep technology 2007 LWW Philadelphia 200
22. Y. To, M. Nishimura, and Y. Fukuchi Long-term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52-week open-labeled study Respirology 16 Suppl. S2 2011 A240
23. J.F. Donohue, D. Singh, and O. Kornmann Safety of indacaterol in the treatment of patients with COPD Int J Chron Obstruct Pulmon Dis 6 2011 477 492